You Position: Home > Paper
Research progress of Delamani in treatment of multidrug-resistant/extensively drug-resistant tuberculosis
( views:341, downloads:156 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Clinical Infectious Diseases
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1674-2397.2020.04.012
- Key Word:
- 德拉马尼;耐多药结核病;广泛耐药结核病;疗效;安全性;Delamanid;Multidrug-resistant tuberculosis;Extensive drug-resistant tuberculosis;Efficacy;Safety
Abstract： The treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is prone to more time-consuming, complex, toxic and ineffective. MDR-TB has low treatment success rate (52%) and high fatality rate (17%), as well as high rate of lost visits(15%), while the treatment success rate of XDR-TB is only 26%. It’s urgent to develop new drugs and chemotherapy regimens to improve the efficacy for MDR/XDR-TB. Delamanid (Dlm) has a strong killing effect on Mycobacterium tuberculosis (MTB) in vitro and in vivo. When MDR-TB patients are treated with optimized background regimen containing Dlm, the two-month sputum negative conversion rate is increased, case fatality is decreased and the prognosis is improved. This article reviews the progress on characteristics, in vitro activity, animal tests, clinical efficacy and safety of Dlm.
- [1]中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识（2019年版）[J].2019,(10).
- [2]Matsumoto, Makoto,Hashizume, Hiroyuki,Tomishige, Tatsuo,etc.OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice.[J].2006,3(11).
- [3]von Groote-Bidlingmaier, Florian,Patientia, Ramonde,Sanchez, Epifanio,etc.Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial[J].2019,7(3).
- [4]Lee Myungsun,Mok Jeongha,Kim Deog Kyeom,etc.Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m[J].2019,20(1).
- [5]Esposito, Susanna,Bosis, Samantha,Tadolini, Marina,etc.Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis A case report and review of the literature[J].2016,95(46).
- [6]Kempker, R. R.,Mikiashvili, L.,Zhao, Y.,etc.Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens[J].2020,71(9).
- [7]Tadolini, Marina,Garcia-Prats, Anthony J.,D'Ambrosio, Lia,etc.Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges[J].2016,48(3).
- [8]Mok, Jeongha,Kang, Hyungseok,Hwang, Soo Hee,etc.Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea[J].2018,73(2).
- [9]Mallikaarjun, Suresh,Wells, Charles,Petersen, Carolyn,etc.Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects[J].2016,60(10).
- [10]A H, Diacon,R, Dawson,M, Hanekom,etc.Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.[J].2011,15(7).
- [11]Jeong Seong,Yang,Kyung Jong,Kim,Hongjo,Choi,etc.Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.[J].2018,38(6).
- [12]Reuter, Anja,Kock, Yulene,Furin, Jennifer,etc.Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa[J].2018,51(6).
- [13]Chen, Xiuhao,Hashizume, Hiroyuki,Tomishige, Tatsuo,etc.Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis[J].2017,61(6).
- [14]Shibata, Masakazu,Shimokawa, Yoshihiko,Sasahara, Katsunori,etc.Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis[J].2017,38(4).
- [15]Ryan,N.J.,Lo,J.H..Delamanid: First global approval[J].2014,74(9).
- [16]Kurve,A.,Danilovits,M.,Levina,K.,etc.Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis[J].2013,41(6).
- [17]Liu, Yongge,Matsumoto, Makoto,Ohguro, Kinue,etc.Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)[J].2018,111.
- [18]Polsfuss, Silke,Hofmann-Thiel, Sabine,Merker, Matthias,etc.Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment[J].2019,69(7).
- [19]Kim, Cheon Tae,Kim, Tae-Ok,Shin, Hong-Joon,etc.Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea[J].2018,51(3).
- [20]Elisa, Schena,Lubov, Nedialkova,Emanuele, Borroni,etc.Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC? MGIT? 960 system.[J].2016.
- [21]Rohit,Sarin,Vikram,Vohra,Neeta,Singla,etc.Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.[J].2019,66(1).
- [22]Mohr, Erika,Ferlazzo, Gabriella,Hewison, Cathy,etc.Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis[J].2019,19(5).
- [23]Keller, Peter M.,Hoemke, Rico,Ritter, Claudia,etc.Determination of MIC Distribution and Epidemiological Cutoff Values for Bedaquiline and Delamanid in Mycobacterium tuberculosis Using the MGIT 960 System Equipped with TB eXiST[J].2015,59(7).
- [24]Ferlazzo, Gabriella,Hughes, Jennifer,Mohr, Erika,etc.Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study[J].2018,18(5).
- [25]Emanuele,Pontali,Rosella,Centis,Lia,D'Ambrosio,etc.Recent evidence on delamanid use for rifampicin-resistant tuberculosis.[J].2019,11(Suppl 3).